AMG 701

DRUG3 trials

Sponsors

Amgen

Conditions

Relapsed/Refractory Multiple Myeloma

Phase 1

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

TerminatedNCT03287908

AmgenRelapsed/Refractory Multiple Myeloma

Start: 2017-11-13End: 2023-06-30Updated: 2025-10-08

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

WithdrawnNCT04998747

AmgenRelapsed/Refractory Multiple Myeloma

Start: 2023-08-29End: 2025-08-28Updated: 2022-09-27

Unknown Phase

AMG 701 Expanded Access Program

Updated: 2024-09-23

Related Papers

Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma.

2026-04-08

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood2020-11-04112 citations

The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models

Blood Advances2020-09-0469 citations

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Blood2019-11-1326 citations

Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment

Blood2018-11-2926 citations

Abstract LB-299: Cynomolgus monkey plasma cell gene signature to quantify the <i>in vivo</i> activity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma

Cancer Research2018-07-017 citations